FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
In a "complete response" letter following the last-minute cancellation of an advisory committee review in June, FDA asks the biotech to do an additional confirmatory study.
In a "complete response" letter following the last-minute cancellation of an advisory committee review in June, FDA asks the biotech to do an additional confirmatory study.